logo
How you could regrow your own teeth instead of having dentures

How you could regrow your own teeth instead of having dentures

Yahoo17-02-2025

Teeth grown in a lab could soon end the need for implants and dentures, experts believe.
Cells from wisdom teeth, combined with pig teeth cells, can be cultivated in a lab and implanted to fill a gap left by a lost tooth, a study has shown.
These lab-grown teeth could be used to replace any type of tooth within 20 years, according to Prof Pamela Yelick, a professor of orthodontics at Tufts University in Boston.
'I 100 per cent think regenerating human teeth can happen,' Prof Yelick told reporters at the American Association for the Advancement of Science (AAAS) annual conference.
'I believe we can do this in my lifetime and I'm in my mid-60s.
'There are so many advances happening in technology, tissue engineering, regenerative medicine and dentistry, and they all feed off each other.'
In a recent study by Prof Yelick, published in the Stem Cells Translational Medicine journal, human-like teeth were grown in pigs in less than four months.
The experiments implanted small human-pig hybrid teeth into the jaw of a porcine study participant, where they completed their growth.
'The study presented here validates a potentially clinically relevant bioengineered tooth replacement therapy for eventual use in humans,' the authors write in the paper.
Half of Britons are missing at least 10 teeth by the age of 75, according to official data, and one in 10 adults have fillings, crowns or bridges that cause discomfort.
Prof Yelick said lab-grown teeth would feel more natural than implants because they keep the nerves and blood circulation.
She said: 'We use cells from wisdom teeth that need to be extracted, and then expand them in the lab to tens of millions of cells.
'Then we can put them onto biodegradable scaffolds and get them to form tooth tissue.
'Even after taking the cells out, freezing them, thawing them and putting them back together they still remember what to do and how to form little tiny teeth.'
The lab begins their growing process before the teeth then continue to grow into their full shape and size in the recipient's gum.
Prof Yelick has now founded a company to turn her scientific breakthroughs into a commercial reality.
Regendodent, the Boston-based company, has already developed one product, RegendoGEL, which is a naturally grown tooth pulp that can be implanted in a root canal.
Because it has not been cleared by the FDA, it is not yet commercially available in the United States.
This product is designed to make root canals last longer than their current lifespan because the standard cement that goes into the hollowed-out root is replaced with a natural tooth pulp.
That pulp is a combination of nerves and blood vessels that promotes continued root development.
Prof Yelick added: 'We're hoping we could make tooth roots that you could put a crown on that would fit properly with your bite.
'It might be resistant to caries or periodontitis so they could be therapeutic in addition to being functional. We're really thinking big.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

UnitedHealth Group received multiple bids for Latin American operations
UnitedHealth Group received multiple bids for Latin American operations

Yahoo

time41 minutes ago

  • Yahoo

UnitedHealth Group received multiple bids for Latin American operations

-- UnitedHealth Group (NYSE:UNH) is considering several offers for its Latin American operations, according to a Reuters report on Monday. The move comes as the largest U.S. health insurer faces challenges that include the departure of its CEO and an alleged criminal accounting investigation. The insurer has been attempting to leave Latin America since 2022, with the sale of its Banmedica subsidiary becoming more urgent in recent months due to increasing pressures on multiple fronts, the report said. So far, UnitedHealth has reportedly received four preliminary bids for Banmedica, which operates in Colombia and Chile, with an estimated value of about $1 billion. In May, UnitedHealth's shares dropped 25.5%, and the year-to-date decline stands at 40%. The company withdrew from Brazil in 2023 and from Peru in March 2025. It aims to secure around $1 billion for Banmedica's operations in Colombia and Chile. The company anticipates setting a deadline for final proposals as early as July. The bids reportedly include offers from Washington, D.C.-based private equity firm Acon Investments, Sao Paulo-based private equity firm Patria Investments, Texas non-profit health organization Christus Health, and Lima-based healthcare and insurance provider Auna. The report mentioned that Auna is currently in discussions with a financial partner. Related articles UnitedHealth Group received multiple bids for Latin American operations Tesla shares slip after double downgrade amid Trump feud fallout What are the three big things in markets now? RBC weighs in

RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program
RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program

Yahoo

timean hour ago

  • Yahoo

RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program

BENGALURU, India, June 09, 2025 (GLOBE NEWSWIRE) -- RenaissThera Private Limited ('RenaissThera'), a Bengaluru-based biotechnology company, announced a major milestone in its obesity drug discovery program targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR). GIPR, an incretin receptor, is a validated target for peptide-based parenteral therapies where both stimulation and inhibition has shown efficacy in treating obesity and its co-morbidities. RenaissThera is developing novel, oral small molecules, both agonists and antagonists, as a more affordable and convenient alternative aiming to expand access for underserved populations in the global obesity market projected to reach USD 38 billion by 2032. Oral small molecules are more economical to manufacture and distribute than peptide-based obesity drugs. These molecules were designed and screened using proprietary AI and ML based platforms, followed by demonstrating in-vitro activity in cell lines and in-vivo activity to impact GIPR in mice to yield 'Hits'. RenaissThera now is advancing these Hits to the Lead optimization program to select candidates for pre-IND studies. RenaissThera is filing 'Composition of Matter' and utility patents for these oral novel small molecule GIPR modulators and continues to expand its innovation portfolio targeting GIP, GLP-1, and apelin receptors in obesity and diabetes. Its AI-powered Innovation Platform, integrating GenAI and machine learning tools, is accelerating the design and optimization of novel small molecules. 'We are grateful to our investors and collaborators for supporting us in reaching this milestone. Our team is focused on pushing candidates toward IND-readiness next year and we are in active discussions with potential pharma partners and investors interested in our obesity program,' said Meena, MD, CEO of RenaissThera. RenaissThera's progress was enabled through its collaboration with VedTechBio Research Private Limited which enabled access to its Agentic AI platform RxAgentAI and discovery expertise. 'We are very pleased with the outcomes of our collaboration with RenaissThera. This milestone further validates our platform and capabilities across key therapeutic areas including obesity, Type 2 diabetes, oncology, and inflammation,' said VedTechBio's Managing Director Sudhir Nagarajan. About RenaissThera RenaissThera is a Bengaluru-based biotech company developing affordable, AI-powered novel small-molecule therapies for high-unmet-need diseases like obesity and diabetes. Its goal is to innovate for underserved populations and expand global access to novel therapies. It leverages India's CRO ecosystem for early-stage R&D to deliver globally relevant innovation. For more information Please contact: Media: Lakshmi Ramakrishna lramakrishna@ Investor & Partnership: Ramkesh Meena bd@

UMMC expands health care access with UMMC Madison
UMMC expands health care access with UMMC Madison

Yahoo

time2 hours ago

  • Yahoo

UMMC expands health care access with UMMC Madison

CANTON, Miss. (WJTV) – The University of Mississippi Medical Center (UMMC) acquired Merit Health Madison, which now operates as UMMC Madison. With 67 licensed beds, officials said the Canton-based hospital will expand UMMC's mission to deliver high-quality, accessible care to more Mississippians while providing additional training opportunities for future health care providers. Lyme-disease isn't the only tick-borne threat. Doctors warn these other diseases are spreading 'As Mississippi's only academic medical center, we must continue to be focused on our three-part mission to educate the next generation of health care providers, conduct impactful research and deliver accessible high-quality health care,' said Dr. LouAnn Woodward, vice chancellor of health affairs. 'Every decision we make is rooted in our mission.' The acquisition was finalized May 1. As the full owner, UMMC will integrate the facility more closely into its academic and health care system. UMMC Madison will continue to provide a wide range of community hospital services, including emergency services, medical-surgical care, ICU, pulmonology, pathology, cardiology, radiology, neurology, nephrology, general surgery and GI services. The hospital will operate as a community hospital. UMMC Madison will also become a training site for medical students, residents and fellows, who will have the opportunity to learn at a community hospital. Close Thanks for signing up! Watch for us in your inbox. Subscribe Now Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store